Japan PMD Act Partial Amendment 2025 — Supply Chain Manager Mandate and GMP Reform (Law No. 37 of 2025)

Background

Japan's domestic generics and active pharmaceutical ingredient (API) supply chain has faced recurrent shortages since 2020, driven by: (a) heavy API import dependence on Chinese contract manufacturers (Zhejiang Huahai, Lupin subsidiaries, etc.); (b) a wave of domestic generics recalls triggered by GMP non-conformities at Japanese generics makers (Kobayashi Kako, Nihon Generic, Sawai) in 2021-23; and (c) concentration risk in a small number of CDMO suppliers for hospital-critical drugs. The amendment is the primary legislative fix — a statutory accountability layer on top of the existing API-diversification funding measures.

The bill (閣法第15号) was submitted to the 217th National Diet on February 12, 2025, passed the House of Representatives on April 3, 2025, passed the House of Councillors on May 14, 2025 (the Diet enactment date cited in discovery), and was formally promulgated as Law No. 37 of 2025 on May 21, 2025.

Key Measures

1. Supply System Manager (安定供給責任者) Designation

Every MAH — domestic and foreign — must appoint a named Supply System Manager who:

• Monitors supply-chain capacity across APIs, intermediates, and finished-goods;
• Files proactive disruption notices to MHLW with timelines and mitigation plans;
• Is a reportable, identified individual (creating named accountability where none existed).

This directly parallels the EU Critical Medicines Act's "critical shortage manager" concept (2025-03-11-eu-critical-medicines-act-proposal) and the US SAPIR EO's strategic API-reserve requirement (2025-08-13-us-eo-sapir-strategic-api-reserve), though it was developed independently from Japan's domestic shortage experience.

2. MHLW Personnel-Replacement Authority

MHLW gains statutory power to order the replacement of the Quality Director, Safety Director, or Supply System Manager if systemic GMP non-compliance or repeated supply failures are found. This is new enforcement leverage — previously MHLW could issue recall orders and business suspensions but lacked the authority to mandate management changes short of criminal referral.

3. Risk-Based GMP Inspection Reform

GMP inspections shift from fixed-cycle to risk-stratified: higher-risk facilities (APIs, sterile injectables, high-concentration-risk products) receive more frequent unannounced inspections; lower-risk generic solid-dosage manufacturers face extended cycles. This aligns Japan's regime with PIC/S best practice and reduces compliance burden on low-risk sites while tightening scrutiny on the shortage-prone API segment.

4. Expanded Conditional Approval

The conditional-approval pathway is broadened to cover any disease "with strong clinical evidence but no alternative treatment," not just specific disease categories. A companion fund supports development of paediatric formulations and rare-disease drugs. Long-term read-through: faster market access for innovative biologics and gene therapies from Takeda, Astellas, and Daiichi Sankyo pipelines, and from foreign entrants filing in Japan.

Enforcement Timeline

Downstream Implications

• Japanese MAHs (Takeda, Astellas, Daiichi Sankyo, Otsuka, Shionogi): Compliance cost to

designate and credential Supply System Managers, build MHLW-reportable shortage-monitoring systems, and upgrade GMP risk documentation. Medium-term positive: forces API-diversification investment that management had deferred.

• Chinese API exporters (Zhejiang Huahai, Lupin JP entities): Heightened MHLW scrutiny of

API-import chains. Any supply disruption by a Chinese API supplier now triggers a named-manager report — creating a paper trail that could inform future strategic sourcing decisions or import restrictions.

• Foreign MAHs with Japan registrations: Must designate a Japanese-resident Supply System

Manager or obtain MHLW dispensation for offshore nominees — compliance cost similar to the EU's Qualified Person-for-Pharmacovigilance requirement.

• CDMOs / contract manufacturers: Risk-based GMP tightening advantages large, well-resourced

CDMOs (Samsung Biologics, Lonza, Catalent JP facilities) and disadvantages small domestic generics CDMOs still remediating 2021-23 GMP failures.

Open Questions

• Will MHLW publish a positive list of "critical drugs" requiring higher-frequency disruption

reporting, analogous to the EU's Union list of critical medicines?

• Interaction with the Economic Security Promotion Act (2022-05-18-japan-economic-security-promotion-act)

designated-critical-goods list — will API supply chains become a Specified Critical Product category requiring domestic stockpile/diversification plans?

• Enforcement trajectory: Will MHLW use the personnel-replacement power against domestic generics

makers, or primarily against foreign MAH nominees?